145 related articles for article (PubMed ID: 12487510)
1. Comments on effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR food evaluation study.
González MA; Polli JE; Morgan JA
Curr Med Res Opin; 2002; 18(7):vii-x. PubMed ID: 12487510
[No Abstract] [Full Text] [Related]
2. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study.
Auiler JF; Liu K; Lynch JM; Gelotte CK
Curr Med Res Opin; 2002; 18(5):311-6. PubMed ID: 12240794
[TBL] [Abstract][Full Text] [Related]
3. Reply to comments by Gonzalez et al. on the CONCERTA, Adderall XR Food Evaluation (CAFE) study.
Auiler JF; Lynch JM; Gelotte CK
Curr Med Res Opin; 2003; 19(1):64-5. PubMed ID: 12661783
[No Abstract] [Full Text] [Related]
4. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis.
Faraone SV; Biederman J; Roe C
J Clin Psychopharmacol; 2002 Oct; 22(5):468-73. PubMed ID: 12352269
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder.
Ermer JC; Adeyi BA; Pucci ML
CNS Drugs; 2010 Dec; 24(12):1009-25. PubMed ID: 21090837
[TBL] [Abstract][Full Text] [Related]
6. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.
Childress A; Mehrotra S; Gobburu J; McLean A; DeSousa NJ; Incledon B
J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979
[TBL] [Abstract][Full Text] [Related]
7. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
[TBL] [Abstract][Full Text] [Related]
8. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
[TBL] [Abstract][Full Text] [Related]
9. Effect of extended release stimulant-based medications on neuropsychological functioning among adolescents with Attention-Deficit/Hyperactivity Disorder.
Wilson HK; Cox DJ; Merkel RL; Moore M; Coghill D
Arch Clin Neuropsychol; 2006 Dec; 21(8):797-807. PubMed ID: 17049803
[TBL] [Abstract][Full Text] [Related]
10. Drugs for ADHD.
Med Lett Drugs Ther; 2020 Jan; 62(1590):9-15. PubMed ID: 31999670
[No Abstract] [Full Text] [Related]
11. [Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guideline. Part 1: overview and recommendations].
Banaschewski T; Coghill D; Santosh P; Zuddas A; Asherson P; Buitelaar J; Danckaerts M; Döpfner M; Faraone SV; Rothenberger A; Sergeant J; Steinhausen HC; Sonuga-Barke EJ; Taylor E
Z Kinder Jugendpsychiatr Psychother; 2008 Mar; 36(2):81-94; quiz 94-5. PubMed ID: 18622938
[TBL] [Abstract][Full Text] [Related]
12. Fed and Fasted Administration of a Novel Extended-Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD.
Weisler RH; Stark JG; Sikes C
Clin Pharmacol Drug Dev; 2018 Feb; 7(2):160-167. PubMed ID: 28544344
[TBL] [Abstract][Full Text] [Related]
13. Flawed attention-deficit/hyperactivity disorder medication comparison.
Adesman A
Pediatrics; 2004 Oct; 114(4):1132; author reply 1132-3. PubMed ID: 15466129
[No Abstract] [Full Text] [Related]
14. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.
Swanson J; Gupta S; Lam A; Shoulson I; Lerner M; Modi N; Lindemulder E; Wigal S
Arch Gen Psychiatry; 2003 Feb; 60(2):204-11. PubMed ID: 12578439
[TBL] [Abstract][Full Text] [Related]
15. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications.
Swanson JM; Lerner M; Wigal T; Steinhoff K; Greenhill L; Posner K; Freid J; Wigal S
J Atten Disord; 2002; 6 Suppl 1():S73-88. PubMed ID: 12685522
[TBL] [Abstract][Full Text] [Related]
16. Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole.
Abbas R; Childress AC; Nagraj P; Rolke R; Berry SA; Palumbo DR
Clin Ther; 2018 May; 40(5):733-740. PubMed ID: 29703430
[TBL] [Abstract][Full Text] [Related]
17. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
18. Adderall XR: long acting stimulant for single daily dosing.
Sallee FR; Smirnoff AV
Expert Rev Neurother; 2004 Nov; 4(6):927-34. PubMed ID: 15853519
[TBL] [Abstract][Full Text] [Related]
19. Quillivant XR--an extended release oral suspension of methylphenidate.
Med Lett Drugs Ther; 2013 Feb; 55(1409):10-1. PubMed ID: 23381227
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
